Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:CRIS NASDAQ:CRTX NASDAQ:MESO NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$11.59+0.7%$11.50$5.01▼$18.70$81.36M0.22105,187 shs13,851 shsCRISCuris$1.67-2.3%$1.73$1.02▼$6.34$20.88M3.8198,924 shs48,265 shsCRTXCortexyme$1.62+1.3%$1.69$1.78▼$40.66$48.85M1.4620,672 shs555,023 shsMESOMesoblast$15.07-3.4%$14.68$6.09▼$22.00$1.93B2.26272,845 shs182,021 shsOCGNOcugen$1.32+12.8%$1.05$0.52▼$1.33$385.84M4.154.31 million shs8.86 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-3.60%-3.60%-6.35%+43.52%+33.84%CRISCuris+0.59%-5.52%-6.56%-25.65%-70.87%CRTXCortexyme0.00%+1.91%-5.33%+17.65%+117.69%MESOMesoblast+0.91%+4.00%-4.00%+33.45%+153.66%OCGNOcugen-2.50%+13.59%+11.43%+7.34%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$11.59+0.7%$11.50$5.01▼$18.70$81.36M0.22105,187 shs13,851 shsCRISCuris$1.67-2.3%$1.73$1.02▼$6.34$20.88M3.8198,924 shs48,265 shsCRTXCortexyme$1.62+1.3%$1.69$1.78▼$40.66$48.85M1.4620,672 shs555,023 shsMESOMesoblast$15.07-3.4%$14.68$6.09▼$22.00$1.93B2.26272,845 shs182,021 shsOCGNOcugen$1.32+12.8%$1.05$0.52▼$1.33$385.84M4.154.31 million shs8.86 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-3.60%-3.60%-6.35%+43.52%+33.84%CRISCuris+0.59%-5.52%-6.56%-25.65%-70.87%CRTXCortexyme0.00%+1.91%-5.33%+17.65%+117.69%MESOMesoblast+0.91%+4.00%-4.00%+33.45%+153.66%OCGNOcugen-2.50%+13.59%+11.43%+7.34%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.80Moderate Buy$21.0081.19% UpsideCRISCuris 3.00Buy$17.00917.96% UpsideCRTXCortexyme 0.00N/AN/AN/AMESOMesoblast 3.20Buy$18.0019.44% UpsideOCGNOcugen 3.00Buy$6.00354.55% UpsideCurrent Analyst Ratings BreakdownLatest OCGN, ATRA, MESO, CRTX, and CRIS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025MESOMesoblastCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/4/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.007/18/2025MESOMesoblastJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.63N/AN/A($16.89) per share-0.69CRISCuris$10.91M1.91N/AN/A($0.71) per share-2.35CRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/AMESOMesoblast$17.20M112.15N/AN/A$4.67 per share3.23OCGNOcugen$4.05M95.27N/AN/A$0.10 per share13.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%11/11/2025 (Estimated)CRISCuris-$43.39M-$4.88N/AN/AN/A-341.24%N/A-102.22%11/13/2025 (Estimated)CRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/AMESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/AOCGNOcugen-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)Latest OCGN, ATRA, MESO, CRTX, and CRIS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32$0.19+$0.51$0.19$4.23 million$17.58 million8/5/2025Q2 2025CRISCuris-$1.99-$0.68+$1.31-$0.68$2.64 million$2.75 million8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A1.701.70CRISCurisN/A0.740.74CRTXCortexymeN/A9.929.92MESOMesoblast0.111.991.77OCGNOcugen9.181.831.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CRISCuris29.97%CRTXCortexyme63.18%MESOMesoblast1.43%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%CRISCuris5.70%CRTXCortexyme27.90%MESOMesoblast18.80%OCGNOcugen4.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3307.02 million6.74 millionOptionableCRISCuris6012.50 million11.79 millionNo DataCRTXCortexyme5530.15 million21.74 millionNot OptionableMESOMesoblast80128.00 million103.93 millionOptionableOCGNOcugen80292.30 million279.77 millionOptionableOCGN, ATRA, MESO, CRTX, and CRIS HeadlinesRecent News About These CompaniesWhy Ocugen (OCGN) Is Up 16.5% After Licensing OCU400 Gene Therapy Rights to KwangdongSeptember 16 at 9:37 AM | finance.yahoo.comOcugen Signs Exclusive License Agreement with KwangdongSeptember 16 at 6:50 AM | tipranks.comOcugen executes licensing agreement with Kwangdong PharmaceuticalSeptember 15 at 11:08 AM | msn.comOcugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 MillionSeptember 15 at 6:11 AM | quiverquant.comQOcugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaSeptember 15 at 6:03 AM | globenewswire.comNuveen LLC Takes Position in Ocugen, Inc. $OCGNSeptember 7, 2025 | marketbeat.comOcugen CEO to Speak at Investor Conferences in New York and MunichSeptember 6, 2025 | msn.comOcugen Enters Subscription Agreement with Carisma TherapeuticsSeptember 5, 2025 | tipranks.comCarisma Therapeutics stock soars after merger agreement with OcugenSeptember 3, 2025 | au.investing.comOcugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025September 2, 2025 | finance.yahoo.comOcugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025September 2, 2025 | globenewswire.comGMT Capital Corp Grows Position in Ocugen, Inc. $OCGNSeptember 1, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Stock Price Up 3% - Here's WhyAugust 27, 2025 | marketbeat.comOcugen (OCGN) Upgraded to Buy: Here's What You Should KnowAugust 26, 2025 | zacks.comOcugen IncAugust 25, 2025 | edition.cnn.comOcugen reports EMA positive advice for acceptability of OCU410STAugust 13, 2025 | msn.comOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to ...August 13, 2025 | bakersfield.comBOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt DiseaseAugust 13, 2025 | globenewswire.comOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 12, 2025 | manilatimes.netMOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 12, 2025 | globenewswire.comOcugen, Inc. Announces $20 Million Securities Purchase Agreement with Janus Henderson InvestorsAugust 8, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCGN, ATRA, MESO, CRTX, and CRIS Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$11.59 +0.08 (+0.70%) Closing price 04:00 PM EasternExtended Trading$11.58 -0.01 (-0.09%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Curis NASDAQ:CRIS$1.67 -0.04 (-2.34%) Closing price 04:00 PM EasternExtended Trading$1.67 0.00 (0.00%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Cortexyme NASDAQ:CRTX$1.62 +0.02 (+1.25%) As of 09/16/2025Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Mesoblast NASDAQ:MESO$15.07 -0.53 (-3.40%) Closing price 04:00 PM EasternExtended Trading$15.10 +0.04 (+0.23%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Ocugen NASDAQ:OCGN$1.32 +0.15 (+12.82%) Closing price 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
